Friedreich’s ataxia (FA) is a rare, autosomal recessive neurodegenerative disease whose natural history and clinical characterization have made significant progress in recent decades. Nevertheless, there is still a lack of sensitive, objective biomarkers that both reliably reflect disease progression and are practicable for clinical studies. The TRACK-FA study, the largest multicenter, multimodal neuroimaging study in FA to date, is now making a decisive contribution. It shows that structural and functional imaging markers not only detect disease-relevant changes, but also correlate with clinical scales. This opens up new avenues for more precise diagnostics, the development of therapies and the shortening of study durations.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Hepatitis B prophylaxis
Vaccination protection for healthcare staff with patient contact – an update
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Adrenogenital syndrome
Clinical care from birth to adulthood
- New approvals, current study data and ADC development
Antibody-drug conjugates in gynecologic oncology
- Type 2 diabetes: cardiovascular risk reduction is realistic
Modern active ingredients and lifestyle – every step counts
- From symptom to diagnosis
Pneumology – Covid-19: a review
- Irritable Bowel Syndrome
Functional disorder of gut-brain interaction – a biopsychosocial concept
- Abdominal aortic aneurysms in primary care